# Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

> **NCT03546426** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 18 (estimated)

## Conditions studied

- Mesothelioma, Malignant
- PD-L1 Negative
- Advanced Cancer
- Progressive Disease

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** Autologous dendritic cells
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03546426
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-12
- **Primary completion:** 2027-01
- **Final completion:** 2028-09
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546426, "Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03546426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*